ClinicalTrials.gg
CompletedNCT01753193Updated Jul 31, 2019Results posted

An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

A Phase 2 interventional study of Anifrolumab in Lupus Erythematosus, Systemic, sponsored by MedImmune LLC. Completed at 57 sites in 13 countries. Open to participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2019-07-31.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
218
Allocation
Not applicable
Ages
18 Years to 68 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Enrollment
10th of 20
218 · median 159
Started
2013
the only one that year
Phase 2
6 of 20
2 open now
Registered
3rd of 20
by date
Lead sponsor
2 of 20
MedImmune LLC

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 10th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 2, and was the 3rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 68 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety of anifrolumab (MEDI-546) in adults with moderate to severe active systemic lupus erythematosus (SLE).

Read the detailed description

This is an open-label extension study to evaluate long-term safety and tolerability of intravenous (IV) anifrolumab in adult participants with moderately-to-severely active SLE. Participants must have completed the qualifying Phase 2 study and meet this study criteria in order to be eligible.

03

Conditions studied

  • Lupus Erythematosus, Systemic

Keywords

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be willing to use 2 methods of effective
  • Must have venous access
  • Must be willing to forego participation in other clinical trials for SLE.

Exclusion criteria

Exclusion Criteria:

  • Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the product
  • Major surgery within 8 weeks before signing form (ICF)
  • Elective major surgery planned during the study period
  • Concomitant Medications within the last 12 weeks: Azathioprine > 200 mg/day, Mycophenolate mofetil/mycophenolic acid > 2.0 g/day, oral, subcutaneous, or intramuscular methotrexate > 25 mg/week
  • A live or attenuated vaccine within 4 weeks of signing the ICF
  • Bacillus of Calmette and Guérin (BCG) vaccine within 1 year of ICF
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    Anifrolumab

    Participants will receive IV infusion of anifrolumab 1000 milligrams (mg) every 4 weeks (Q4W) from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter will receive 300 mg Q4W for up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.

    Biological: Anifrolumab

Interventions

  • BiologicalAnifrolumab

    Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.

    Also known as: MEDI-546

06

What researchers measure

Primary outcomes

  1. Number of Particpants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: From first dose of study drug (Day 1) through 168 weeks

  2. Number of Participants With Adverse Events Resulting in Discontinuation (DAEs) of Anifrolumab

    Number of participants with DAEs are reported.

    Time frame: From first dose of study drug (Day 1) through 168 weeks

  3. Number of Participants With Adverse Events of Special Interest (AESIs)

    An AESI is scientific and medical concern specific to understanding of the study drug. An AESI may be serious or non-serious. Number of participants with AESIs are reported.

    Time frame: From first dose of study drug (Day 1) through 168 weeks

Secondary outcomes

  1. Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Anifrolumab

    The number of participants with positive serum antibodies to anifrolumab at anytime (including baseline) are reported.

    Time frame: Baseline (Pre-dose on Day 1) up to Week 168

  2. Anti-Drug Antibodies (ADA) Titer to Anifrolumab

    Median ADA titer in participants with ADA-positive assessments and reportable ADA titer results are reported.

    Time frame: Baseline (Pre-dose on Day 1) up to Week 168

  3. Number of ADA-positive Participants With Decreased Serum Concentration of Anifrolumab

    Number of participants with decreased serum concentration of anifrolumab due to ADA-positive results are reported.

    Time frame: Baseline (Pre-dose on Day 1) up to Week 168

  4. Number of ADA-positive Participants With Decreased Pharmacodynamics Response of Anifrolumab

    Number of participants with decreased pharmacodynamic response of anifrolumab due to ADA-positive results are reported.

    Time frame: Baseline (Pre-dose on Day 1) up to Week 168

  5. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Global Score for ADA Positive Participants

    The SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).

    Time frame: Baseline (Pre-dose on Day 1); and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 160, and 168

  6. Number of ADA-positive Participants With TEAEs and TESAEs

    The number of ADA-positive participants with TEAEs and TESAEs are reported.

    Time frame: Baseline (Pre-dose on Day 1) up to Week 168

07

Results

Posted Jul 31, 2019

Participant flow

The study was conducted from 28 Mar 2013 to 18 Jul 2018.

Participant flow — Overall Study
MilestoneAnifrolumab
Started218
Completed172
Not completed46
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up6
Withdrew: Death1
Withdrew: Other16

Outcome measures

PrimaryNumber of Particpants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
From first dose of study drug (Day 1) through 168 weeks
Reported as:
Count of participants · Participants
Number of Particpants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsAnifrolumab
TEAEs170
TESAEs50
PrimaryNumber of Participants With Adverse Events Resulting in Discontinuation (DAEs) of Anifrolumab

Number of participants with DAEs are reported.

Time frame:
From first dose of study drug (Day 1) through 168 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Resulting in Discontinuation (DAEs) of Anifrolumab
ParticipantsAnifrolumab
Number of Participants With Adverse Events Resulting in Discontinuation (DAEs) of Anifrolumab17
SecondaryNumber of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Anifrolumab

The number of participants with positive serum antibodies to anifrolumab at anytime (including baseline) are reported.

Time frame:
Baseline (Pre-dose on Day 1) up to Week 168
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Anifrolumab
ParticipantsAnifrolumab
Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Anifrolumab5
SecondaryAnti-Drug Antibodies (ADA) Titer to Anifrolumab

Median ADA titer in participants with ADA-positive assessments and reportable ADA titer results are reported.

Time frame:
Baseline (Pre-dose on Day 1) up to Week 168
Reported as:
Median · Antibody titers
Anti-Drug Antibodies (ADA) Titer to Anifrolumab
Antibody titersAnifrolumab
Anti-Drug Antibodies (ADA) Titer to Anifrolumab120 (30 to 120)
SecondaryNumber of ADA-positive Participants With Decreased Serum Concentration of Anifrolumab

Number of participants with decreased serum concentration of anifrolumab due to ADA-positive results are reported.

Time frame:
Baseline (Pre-dose on Day 1) up to Week 168
Reported as:
Count of participants · Participants
Number of ADA-positive Participants With Decreased Serum Concentration of Anifrolumab
ParticipantsAnifrolumab
Number of ADA-positive Participants With Decreased Serum Concentration of Anifrolumab1
SecondaryNumber of ADA-positive Participants With Decreased Pharmacodynamics Response of Anifrolumab

Number of participants with decreased pharmacodynamic response of anifrolumab due to ADA-positive results are reported.

Time frame:
Baseline (Pre-dose on Day 1) up to Week 168
Reported as:
Count of participants · Participants
Number of ADA-positive Participants With Decreased Pharmacodynamics Response of Anifrolumab
ParticipantsAnifrolumab
Number of ADA-positive Participants With Decreased Pharmacodynamics Response of Anifrolumab1
SecondarySystemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Global Score for ADA Positive Participants

The SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).

Time frame:
Baseline (Pre-dose on Day 1); and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 160, and 168
Reported as:
Mean · Units on Score
Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Global Score for ADA Positive Participants
Units on ScoreAnifrolumab
Baseline7.8 ± 7.6
Week 125 ± 2.0
Week 241.5 ± 1.9
Week 362.0 ± 2.3
Week 481.8 ± 2.0
Week 602.0 ± 1.6
Week 724.0 ± 5.7
Week 843.0 ± 1.4
Week 963.0 ± 1.4
Week 1084.0 ± 0.0
Week 1205.0 ± 1.4
Week 1324.0 ± 0.0
Week 1447.0 ± 7.1
Week 1566.0 ± 2.8
Week 1602.0 ± 2.8
Week 1682.0 ± 2.8
SecondaryNumber of ADA-positive Participants With TEAEs and TESAEs

The number of ADA-positive participants with TEAEs and TESAEs are reported.

Time frame:
Baseline (Pre-dose on Day 1) up to Week 168
Reported as:
Count of participants · Participants
Number of ADA-positive Participants With TEAEs and TESAEs
ParticipantsAnifrolumab
TEAEs5
TESAEs1
PrimaryNumber of Participants With Adverse Events of Special Interest (AESIs)

An AESI is scientific and medical concern specific to understanding of the study drug. An AESI may be serious or non-serious. Number of participants with AESIs are reported.

Time frame:
From first dose of study drug (Day 1) through 168 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs)
ParticipantsAnifrolumab
Herpes zoster11
Drug hypersensitivity1
Hypersensitivity2
Infusion related reaction4
Nausea1
Hodgkin's disease1
Latent tuberculosis5
Hypersensitivity vasculitis1
Vasculitis1

Adverse events

Collected over From first dose of study drug (Day 1) through 168 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anifrolumab1/218 (0.5%)50/218 (22.9%)164/218 (75.2%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventAnifrolumab
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders5/218
PneumoniaInfections and infestations4/218
BronchitisInfections and infestations2/218
Chikungunya virus infectionInfections and infestations2/218
GastroenteritisInfections and infestations2/218
Post procedural infectionInfections and infestations2/218
Urinary tract infectionInfections and infestations2/218
Femur fractureInjury, poisoning and procedural complications2/218
OsteonecrosisMusculoskeletal and connective tissue disorders2/218
Spinal column stenosisMusculoskeletal and connective tissue disorders2/218
Most frequent other events
Showing 10 of 303
Most frequent other events
EventAnifrolumab
NasopharyngitisInfections and infestations32/218
BronchitisInfections and infestations28/218
Upper respiratory tract infectionInfections and infestations20/218
HeadacheNervous system disorders14/218
Urinary tract infectionInfections and infestations13/218
DiarrhoeaGastrointestinal disorders11/218
Herpes zosterInfections and infestations10/218
PharyngitisInfections and infestations10/218
InfluenzaInfections and infestations9/218
SinusitisInfections and infestations8/218

Baseline characteristics

As-treated population included all participants who received any dose of study drug in the OLE study.

Age, Continuous
Age, Continuous(Years)Anifrolumab
Mean40.8 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Anifrolumab
Female203
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Anifrolumab
Hispanic or Latino104
Not Hispanic or Latino114
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Anifrolumab
American Indian or Alaska Native4
Asian11
Native Hawaiian or Other Pacific Islander0
Black or African American29
White87
More than one race2
Unknown or Not Reported85
08

Study locations

57 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    La Palma, California 90623, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Los Angeles, California 90095-1670, United States
  • Research Site
    Palm Desert, California 92260, United States
  • Research Site
    Upland, California 91786, United States
  • Research Site
    Ocala, Florida 34474, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Atlanta, Georgia 30281, United States
  • Research Site
    Stockbridge, Georgia 30281, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Las Cruces, New Mexico 88011, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Raleigh, North Carolina 27617, United States
  • Research Site
    Columbus, Ohio 43203, United States
  • Research Site
    Tulsa, Oklahoma 74104, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77034, United States
  • Research Site
    Spokane, Washington 99204, United States
  • Research Site
    Rio de Janeiro, 22040-042, Brazil
  • Research Site
    Sao Paulo, 04032-060, Brazil
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Barranquilla, Colombia
  • Research Site
    Bogota, Colombia
  • Research Site
    Bucaramanga, Colombia
  • Research Site
    Chia, Colombia
  • Research Site
    Medellin, Colombia
  • Research Site
    Brno, Czechia
  • Research Site
    Praha 2, Czechia
  • Research Site
    Debrecen, Hungary
  • Research Site
    Gwangju, Korea, Republic of
  • Research Site
    Seodaemun-gu, Korea, Republic of
  • Research Site
    Suwon-si, 16499, Korea, Republic of
  • Research Site
    Guadalajara, Mexico
  • Research Site
    Leon, Mexico
  • Research Site
    Mexico, Mexico
  • Research Site
    Toluca, Mexico
  • Research Site
    Arequipa, Peru
  • Research Site
    Lima, 15033, Peru
  • Research Site
    Lima, Peru
  • Research Site
    Bialystok, 15-297, Poland
  • Research Site
    Krakow, 31-011, Poland
  • Research Site
    Nadarzyn, 05-830, Poland
  • Research Site
    Poznan, 61-397, Poland
  • Research Site
    Iasi, 700661, Romania
  • Research Site
    Chiayi, 622, Taiwan
  • Research Site
    Zhongzheng District, Taiwan
  • Research Site
    Donetsk, Ukraine
  • Research Site
    Kyiv, Ukraine
  • Research Site
    Ternopil, Ukraine
  • Research Site
    Vinnitsya, 21029, Ukraine
  • Research Site
    Vinnytsia, 21018, Ukraine
09

References and documents

Publications

  • Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, Tummala R. Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study. Arthritis Rheumatol. 2021 May;73(5):816-825. doi: 10.1002/art.41598. Epub 2021 Mar 24. Erratum In: Arthritis Rheumatol. 2021 Aug;73(8):1570. doi: 10.1002/art.41903. PubMed 33225631 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. Additional information can be found on astrazenecaclinicaltrials.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Jul 2018, 63 months.

Results were first posted in Jul 2019, 1 year after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 63 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2012
First posted
Dec 20, 2012
StartActual
Mar 28, 2013
Primary completionActual
Jul 18, 2018
CompletionActual
Jul 18, 2018
Results first posted
Jul 31, 2019
Last update
Jul 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01753193
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Dec 20, 2012
Start date
Mar 28, 2013
Primary completion
Jul 18, 2018
Completion
Jul 18, 2018
Results posted
Jul 31, 2019
Last update
Jul 31, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion